Skip to content
lifestyle.getpetsavvy.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cerenome, Inc.
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
November 4, 2026
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
October 29, 2026
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
October 27, 2026
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
October 21, 2026
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
October 8, 2026
Cerenome Launches CNSide® CSF Molecular Profile Tests
October 6, 2026
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
September 30, 2026
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
September 25, 2026
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
September 22, 2026
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
September 16, 2026
1
2
Next Page
→